

In addition, the above-mentioned Securities Regulator, the Company and its directors and officers have taken all necessary and effective measures to prevent, and to correct any irregularities in the Company's financial reporting process, and to ensure that the Company's financial reporting process is in compliance with the applicable laws and regulations. The Company and its directors and officers have also taken all necessary and effective measures to prevent, and to correct any irregularities in the Company's financial reporting process, and to ensure that the Company's financial reporting process is in compliance with the applicable laws and regulations. The Company and its directors and officers have also taken all necessary and effective measures to prevent, and to correct any irregularities in the Company's financial reporting process, and to ensure that the Company's financial reporting process is in compliance with the applicable laws and regulations.

The Company and its directors and officers have taken all necessary and effective measures to prevent, and to correct any irregularities in the Company's financial reporting process, and to ensure that the Company's financial reporting process is in compliance with the applicable laws and regulations.

Shareholders and potential investors of the Company are reminded that the information provided in this announcement is based on the currently available information to the Board. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

B e n e B a d
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

Shenzhen, PRC
January 30, 2024

A, a he da e, f hi, a ce e, he e ec i e di ec, , f he C, a a e M. Li Li, M, Li Ta M. Sha Y a d M. Zha g Pi g; a d he i de e de e ec i e di ec, , f he C, a a e D. L Ch a M. H a g Pe g a d M. Yi Mi g.